source
- FDA approves Takeda's orexin drug for narcolepsy type 1Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1. The decision ends a closely watched commercial race to bring an orexin-based therapy to market. With a…
- LifeMine Therapeutics secures $188 million Series E funding from Gates, Bezos and othersLifeMine Therapeutics, a Massachusetts biotech, recently completed a $188 million Series E round, attracting billionaire investors Bill Gates and Jeff Bezos. The funding follows a $75 million Seri…